Affiliations: [a] Department of Oncology, District Hospital, Leśna, Poland | [b] Department of Anatomy, Wrocław Medical University, Wrocław, Poland | [c] Department of Animal Product Technology and Quality Management, Wrocław University of Environmental and Life Sciences, Wrocław, Poland | [d] Department of Pharmaceutical Biochemistry, Wrocław Medical University, Wrocław, Poland | [e] Department of Physiology, Wrocław Medical University, Wrocław, Poland | [f] Department of Basic Sciences, Wrocław Medical University, Wrocław, Poland
Correspondence:
[*]
Corresponding author: Bohdan Gworys, Department of Anatomy, Wrocław Medical University, ul. Chałubińskiego 6a, 50-368 Wrocław, Poland. E-mail: bgworys@gmail.com.
Abstract: Background:Complement information about the share the role of antipapain activity in serum people with breast cancer. Objective:We measured the activity of cysteine peptidase inhibitors in the sera of 150 patients with breast cancer. Patients were divided into four groups depending on the cancer type and treatment method. We also analysed the control group. The activity of cysteine peptidase inhibitors was defined as a ’defensiveness’ marker. Methods:The activity of cysteine peptidase inhibitors was measured against papain using the colorimetric method and the BANA substrate. Results:The highest activity of enzymes was found in the group of patients with BC and hereditary predisposition to it, and the lowest activity was found in patients after surgical treatment. Conclusion:The activity of cysteine peptidase inhibitors in serum was measured against papain. We found that the activity levels were correlated with the cancer stage and treatment method. The lowest activity was found in patients after surgical treatment; the highest in women with active cancer and a hereditary predisposition to it.
